Parallax Volatility Advisers
ITCI

Parallax Volatility Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parallax Volatility Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-741
Closed -$19K – 3571
2020
Q3 		$19K Buy
+741
New +$16.9K ﹤0.01% 2941
2019
Q3 		– Sell
-118,884
Closed -$1.54M – 3678
2019
Q2 		$1.54M Buy
118,884
+22,471
+23% +$288K ﹤0.01% 1127
2019
Q1 		$1.17M Buy
+96,413
New +$1.23M ﹤0.01% 1206
2018
Q1 		– Sell
-10,110
Closed -$146K – 4520
2017
Q4 		$146K Sell
10,110
-87,978
-90% -$1.36M ﹤0.01% 2531
2017
Q3 		$1.55M Buy
+98,088
New +$1.44M ﹤0.01% 922

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Parallax Volatility Advisers's ITCI Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2020, closing a stake of 741 shares — an estimated $19K sold.

Parallax Volatility Advisers first reported a position in ITCI in Q3 2017 and held it in 5 quarters. The position peaked at $1.55M in Q3 2017. 178 funds tracked by Wall St. Rank hold ITCI as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 741 Intra-Cellular Therapies Inc. shares in Q4 2020, an estimated $19K.
  • Parallax Volatility Advisers first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Intra-Cellular Therapies Inc. position peaked at $1.55M in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.